Novartis pushes on with iscalimab after transplant disappointment
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
Humanigen claims a Covid-19 win with lenzilumab
But the company focused on a modified intent-to-treat analysis of its pivotal trial.
Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Glaxo fails to win an Oscar
There might be a use for Glaxo’s anti-Covid-19 antibody otilimab in old patients, but repeating Actemra’s trick will not be easy.
Incyte’s Jakafi disappoints in severe Covid-19
As Jak inhibition takes a big knock, attention turns to other immunosuppressive mechanisms being studied in very ill Covid-19 patients.
Scanning the horizon for future Covid-19 treatments
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
June rush drives near-record quarter for biotech flotations
Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.
